Despite the strong association between intraoperative hypotension and postoperative adverse cardiovascular outcomes, a new study suggests universally targeting higher blood
Continue reading »
Home »
CV prognosis good at six months after hospitalization for MIS-C
(HealthDay)—Children with multisystem inflammatory syndrome in children (MIS-C) treated with immunomodulators have favorable outcomes at six months, with normalization of
Continue reading »
New Natriuretic Peptide Shows Unique Biomarker Potential
The biomarker C-type natriuretic peptide (CNP) is under exploration as both a risk predictor and a target for new drug
Continue reading »
FDA to Cut Broadly Worded Statin Pregnancy Contraindication
The US Food and Drug Administration (FDA) aims to update the labeling on all statins to remove the drugs’ blanket
Continue reading »
Both Higher Alcohol Intake and Genetic Predisposition Tied to CVD
Cardiovascular disease risk is associated with alcohol intake in general, but variations in risk exist with levels of intake, based
Continue reading »
Novel IL-6 Antibody Slashes CRP up to 92% in High-risk ASCVD
Inhibition of interleukin (IL)-6 with ziltivekimab reduces multiple biomarkers of inflammation and thrombosis in patients at high atherosclerotic risk with
Continue reading »
Ertugliflozin Noninferior for CV Outcomes in T2DM With ASCVD
THURSDAY, Oct. 15, 2020 — Ertugliflozin is noninferior to placebo with respect to major adverse cardiovascular events among patients with
Continue reading »
Serelaxin does not lower CV death in acute heart failure
(HealthDay)—An infusion of serelaxin does not result in a lower incidence of death from cardiovascular causes or worsening of heart
Continue reading »
Erectile dysfunction independently tied to CV events
(HealthDay)—Erectile dysfunction (ED) is independently associated with cardiovascular disease (CVD), according to a research letter published online June 11 in
Continue reading »